With thanks to CAC2 member Laurie Orloski for taking notes for us during this year’s Childhood Cancer Congressional Caucus Summit: The Congressional Childhood Cancer Caucus_2015_notes FINAL
Read moreAll posts tagged: Advocacy
CAC2 Webinar–Advancing the Quality of Life: Strategic Agenda for Childhood Cancer Through Innovation, Ingenuity, and Advocacy
During our February All-Member webinar our guest, Rebecca Kirch, Director of Quality of Life and Survivorship for the American Cancer Society, discussed and answered questions about the quality of life strategic agenda and its specific relevance for childhood cancer, including information about the upcoming Institute of Medicine March workshop on comprehensive childhood cancer care. Research has improved treatments and boosted survival in some types of pediatric cancer, but treatment toxicities still cause a majority of children to experience distressing side effects and late effects — conditions that often cause significant suffering that continues into adulthood and can last a lifetime. [...] Read more
Protected: CAC2 Advocacy Interest Group Meeting Notes–February 2015
There is no excerpt because this is a protected post.
Read more
A Roundtable Discussion to Shape the Future of Childhood Cancer Policy–SLIDE DECK
On Wednesday, December 3 CAC2 invited members Steve Crowley and Vickie Buenger to explain the unique opportunity CAC2 has to shape a national strategy for childhood cancer policy. Continuing Community Conversation: Roundtable Discussion to Shape the Future of Childhood Cancer Policy View the webinar slide deck.
Read more
CAC2 Webinar–Dr. Jeffrey Skolnik, Basics of Pediatric Drug Development
On Wednesday, November 12, CAC2 had the privilege of hosting Jeffrey Skolnik, MD, US Medical Affairs Leader, Oncology, GlaxoSmithKline and Attending Physician, Children’s Hospital of Philadelphia. He presented our November All-Member webinar about the industry perspective in pediatric oncology drug development. The views he expresses are his personal observations and not the official position of GSK or any other pharmaceutical company. https://youtu.be/Txrak33zR60 Read more
Pediatric Cancer: Major Advances, Major Challenges – Notes from the 5th Annual Childhood Cancer Caucus
The Congressional Childhood Cancer Caucus Presents Pediatric Cancer: Major Advances, Major Challenges 5th Annual Childhood Cancer Caucus Friday, September 19, 2014 9:00 – 10:30 a.m. Congressional Auditorium, US Capitol Visitors Center Co-Chairs: Congressman Michael T. McCaul (R-TX) Congressman Chris Van Hollen (D-MD) Keynote speaker: Dr. Francis Collins, Director, National Institutes of Health (NIH) Speakers: Dr. Ronald DePinho, President, MD Anderson Cancer Center Dr. Amrit Ray, Chief Medical Officer, Johnson & Johnson – Janssen Pharmaceuticals Notes: by CAC2 Member Laurie Orloski Opening remarks Vickie Buenger, President of the Coalition of Childhood Cancer (CAC2) Vickie Buenger kicked off the Caucus by welcoming […]
Read more
CAC2 Webinar–Dr. Peter Adamson and Danielle Leach–NCI Funding and Action Day–SLIDE DECKS
On May 22, we were privileged to host Dr. Peter Adamson speaking on the history and outlook for NCI Funding and Danielle Leach providing an overview for in-person and virtual participation in the Alliance for Childhood Cancer Action Day coming up next month. Thanks to both of these articular guests for their thoughtful and insightful answers to all of our questions. Peter Adamson's Slide Deck Danielle Leach's Slide Deck Read more
Protected: CAC2 Advocacy Conference Call Notes from April 8
There is no excerpt because this is a protected post.
Read moreProtected: CAC2 April Advocacy Call–Agenda & Feb. meeting notes
There is no excerpt because this is a protected post.
Read moreProtected: Advocacy Call:
There is no excerpt because this is a protected post.
Read more